10-Q
Quarterly Report
AGENUS INC
AGEN
NASDAQ
CIK: 1098972
File #: 000-29089
Balance Sheet
52 line items · 2 periods
XBRL
| Item | Mar 31, 2025 | Dec 31, 2024 |
|---|---|---|
ASSETS | ||
Cash and cash equivalents | 18,488,000 | 40,437,000 |
Estimated Fair Value | 5,560,000 | 6,954,000 |
Institutional Money Market Funds - Cost | 5,560,000 | 6,954,000 |
Institutional Money Market Funds - Estimated Fair Value | 5,560,000 | 6,954,000 |
Cost | 5,560,000 | 6,954,000 |
MiNK Therapeutics, Inc. | — | 4,600,000 |
Accounts receivable | 354,000 | 407,000 |
Prepaid expenses | 1,872,000 | 2,315,000 |
Other current assets | 2,424,000 | 2,415,000 |
Total current assets | 23,138,000 | 45,574,000 |
Property, plant and equipment, net of accumulated amortization and depreciation of $75,878 and $72,553 at March 31, 2025 and December 31, 2024, respectively | 117,030,000 | 120,087,000 |
Operating lease right-of-use assets | 27,046,000 | 27,308,000 |
Goodwill | 24,092,000 | 24,092,000 |
Acquired intangible assets, net of accumulated amortization of $17,071 and $16,986 at March 31, 2025 and December 31, 2024, respectively | 3,291,000 | 3,376,000 |
Other long-term assets | 5,604,000 | 5,834,000 |
Total assets | 200,201,000 | 226,271,000 |
LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
Current portion, long-term debt | 731,000 | 2,698,000 |
Other services | 585,000 | 81,000 |
Debentures | 146,000 | 146,000 |
2015 Subordinated Notes | — | 2,471,000 |
Current portion, liability related to sale of future royalties and milestones | 99,330,000 | 111,978,000 |
Current portion, deferred revenue | 14,000 | 31,000 |
Current portion, operating lease liabilities | 2,525,000 | 2,446,000 |
Accounts payable | 64,240,000 | 61,470,000 |
Accrued liabilities | 36,444,000 | 34,961,000 |
Other current liabilities | 5,020,000 | 7,817,000 |
Total current liabilities | 208,304,000 | 221,401,000 |
Long-term debt, net of current portion | 32,846,000 | 30,473,000 |
2015 Subordinated Notes | 10,132,000 | 10,500,000 |
Promissory Note | 22,714,000 | 19,973,000 |
Liability related to sale of future royalties and milestones, net of current portion | 225,563,000 | 224,389,000 |
Deferred revenue, net of current portion | 1,143,000 | 1,143,000 |
Operating lease liabilities, net of current portion | 53,982,000 | 54,551,000 |
Other long-term liabilities | 761,000 | 738,000 |
STOCKHOLDERS" DEFICIT | ||
Series A-1 convertible preferred stock | 0 | 0 |
Common stock, par value $0.01 per share; 800,000,000 shares authorized; 26,563,545 and 23,634,670 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 266,000 | 236,000 |
Additional paid-in capital | 1,867,500,000 | 1,857,662,000 |
Accumulated other comprehensive loss | (1,468,000) | (1,398,000) |
Accumulated deficit | (2,208,146,000) | (2,182,880,000) |
Total stockholders' deficit attributable to Agenus Inc. | (341,848,000) | (326,380,000) |
Non-controlling interest | 19,450,000 | 19,956,000 |
Total stockholders' deficit | (322,398,000) | (306,424,000) |
Accumulated Other Comprehensive Income (Loss) | (1,468,000) | (1,398,000) |
Series A-1 convertible preferred stock - Preferred Stock | 0 | 0 |
Additional Paid-in Capital | 1,867,500,000 | 1,857,662,000 |
Accumulated Deficit | (2,208,146,000) | (2,182,880,000) |
Common Stock | 266,000 | 236,000 |
Non-controlling Interest | 19,450,000 | 19,956,000 |
Total liabilities and stockholders' deficit | 200,201,000 | 226,271,000 |